KMDA trades 50.5% below Wall Street's consensus target of $11.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KMDA achieves its forward estimates and maintains a stable P/E multiple of 17.1x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Kamada Ltd. (KMDA) has a Wall Street consensus price target of $11.00, based on estimates from 6 covering analysts. With the stock currently trading at $7.19, this represents a potential upside of +50.5%. The company has a market capitalization of $415M.
Analyst price targets range from a low of $11.00 to a high of $11.00, representing a 0% spread in expectations. The median target of $11.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KMDA trades at a trailing P/E of 19.4x and forward P/E of 17.1x. Analysts expect EPS to grow +23.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.41, with bear and bull scenarios of $4.04 and $8.45 respectively. Model confidence stands at 42/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ADMAADMA Biologics, Inc. | $2.0B | $8.57 | $21.00 | +152.7% | Buy | 10.0x | 10 |
GRFSGrifols, S.A. | $6.2B | $7.28 | — | — | Buy | 8.8x | 8 |
BIOBio-Rad Laboratories, Inc. | $7.6B | $280.96 | $321.67 | +13.9% | Buy | 31.2x | 14 |
BHVNBiohaven Ltd. | $1.6B | $15.50 | $17.60 | +29.7% | Buy | — | 25 |
RAREUltragenyx Pharmaceutical Inc. | $2.9B | $29.03 | $48.36 | +76.2% | Buy | — | 33 |
PRTAProthena Corporation plc | $479M | $9.15 | $19.00 | +112.8% | Buy | 191.2x | 28 |
ACADACADIA Pharmaceuticals Inc. | $3.8B | $22.09 | $33.67 | +55.7% | Buy | 55.6x | 37 |
FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
CSLCarlisle Companies Incorporated | $14.8B | $360.96 | $408.75 | +13.2% | Buy | 17.2x | 26 |
BAXBaxter International Inc. | $10.1B | $19.66 | $20.71 | +4.1% | Hold | 10.4x | 36 |
Quick answers to the most common questions about buying KMDA stock.
The consensus Wall Street price target for KMDA is $11, representing 50.5% upside from the current price of $7.19. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KMDA has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $11 implies 50.5% upside from current levels.
With a forward P/E of 17.0994x, KMDA trades at a relatively low valuation. The consensus target of $11 implies 50.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $11 for KMDA, while the most conservative target is $11. The consensus of $11 represents the median expectation. Our quantitative valuation model projects a bull case target of $8 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
KMDA is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KMDA stock forecast based on 6 Wall Street analysts shows a consensus price target of $11, with estimates ranging from $11 (bear case) to $11 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $4/$8.
Our quantitative valuation model calculates KMDA's fair value at $6 (base case), with a bear case of $4 and bull case of $8. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.
KMDA trades at a forward P/E ratio of 17.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on KMDA, with a "Buy" consensus rating and $11 price target (50.5% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KMDA analyst price targets range from $11 to $11, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11 consensus represents the middle ground. Our model's $4-$8 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.